Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon/Thalidomide and Pamidronate for Patients With Multiple Myeloma

NCT00004088 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT00004088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon/Thalidomide and Pamidronate for Patients With Multiple Myeloma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
April 13, 1999
Completion date
January 9, 2018
Enrollment
77 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm